John Mcsweeney Email & Phone Number

Boston, MA, US

Cambridge, Massachusetts, United States

Cambridge, Massachusetts, United States

• Point person for the ASMD Global Brand Team and Global Project Team, providing market access expertise.
• Key liaison for markets that are preparing for Xenpozyme launch.
• Partnered with HEVA in identifying payer needs for evidence generation activities, and with public affairs, medical and commercial on stakeholder engagement to support payer negotiations.
• Updated Global Pricing policy to align with achievement of early launch markets and prioritization of countries.

• Managed market access and pricing strategy for the launch of Avalglucosidase Alfa for Pompe disease and Olipudase Alfa for Acid Sphingomyelinase Deficiency (ASMD), as well as the already marketed therapy (Myozyme) for.
• Worked with global access team on key deliverables, Global Pricing guidance, Payer Value Story, Payer, Objection Hander, and mock negotiations for key markets.
• Created contracting guidance for Xenpozyme. Developed the guidance into training sessions for key launch markets.
• Managed changes to the launch sequence through regulatory and orphan drug status changes in key markets. I worked with regulatory, commercial, and supply to manage all launch sequence change challenges, including.
• Support development of key pricing & market access deliverables; tailor global deliverables for emerging market audience.

Cambridge, Massachusetts, United States

• Managed Payer research project in US and EU5 markets for Phase 2 clinical product for ASMD.
• Support ASMD brand team in launch preparation. Including target price, launch sequence, payer drivers and barriers.
• Develop and manage payer research project for phase 3 clinical ADPKD product in EU5. The goal was to test additional value drivers and data that may be required to launch against an existing product with no head to.
• Work on cross functional team to support launch decisions for multi-indication product.
• Worked on Brand Planning and Long-Term forecasting for Rare Disease.
• Update pricing policies for existing launched drugs in Rare Disease portfolio.

Cambridge, Massachusetts, United States

• Coordinated launch of a new online price and reimbursement database PriceRight from EverSana. Assist with design, conversion of all data, and trained global affiliates and business unit leaders.
• Principal evaluator of software for new International Reference Pricing and Launch Sequence Optimization for evaluating revenue impact of price changes and developing ideal launch sequence of countries for new products.
• Responsibilities include performing historic and projected price erosion analysis for all products, price parity analysis with Cerezyme for the Cerdelga launch, researching Multiple Sclerosis market competitors, and.
• In 2017 converted to Sanofi wide pricing database from Model N.

Cambridge, MA

• Support pricing and reimbursement activities for Multiple Sclerosis and Rare Disease business units.
• Model impact of International Reference Pricing policies on future revenues using a software tool from Inpharmation. Optimize the tool for Genzyme products with reference policy information from all local affiliates.
• Created new quarterly dashboards for the Global Pricing Committee to graphically display price changes, trends, and end of quarter prices per pack and as an average annual cost per patient.
• Maintain, analyze internally, and report externally pricing and reimbursement information for all countries and products.
• Collaborate with local affiliates for price change proposals to the Global Pricing Committee. This includes ensuring accuracy of price data and P&L, providing potential global impact and price corridors, and editing.

Shelton, CT

Westbrook, ME

Wilmington, MA

Master Of Business Administration (M.B.A.)

Bachelor’S Degree, Bachelor Of Science In Chemistry